Medicenna - President and CEO, Fahar Merchant.
President and CEO, Fahar Merchant.
Source: The International Cytokine and Interferon Society.
  • Medicenna (MDNA) has priced its 13,333,334-unit marketed public offering at US$1.50 per unit
  • The company intends to use the funds to further develop its product pipeline
  • It expects the offering to close on or around August 11, 2022
  • Medicenna is a clinical-stage immunotherapy company focused on fine-tuning the immune system to combat the most challenging diseases
  • Medicenna Therapeutics (MDNA) is down by 41.85 per cent trading at $1.32 per share

Medicenna (MDNA) has priced its 13,333,334-unit marketed public offering at US$1.50 per unit.

Each unit is comprised of one common share and one common share purchase warrant.

Each warrant entitles the holder to purchase one common share priced at US$1.85 for 60 months following the date of closing.

It intends to use the net proceeds to fund the clinical development of MDNA11, the pre-clinical development of a BiSKIT candidate, as well as for working capital and general corporate purposes.

Guggenheim Securities is acting as sole book-running manager with Bloom Burton Securities acting as co-manager.

The company expects the offering to close on or around August 11, 2022.

Medicenna is a clinical-stage immunotherapy company focused on fine-tuning the immune system to combat the most challenging diseases, including a broad range of cancers.

Medicenna Therapeutics (MDNA) is down by 41.85 per cent trading at $1.32 per share as of 1:48 pm EST.


More From The Market Online

Avicanna launches 10% CBD (THC free) formula in Canada

Avicanna (TSX:AVCN) launches RHO Phyto Micro Drop 100, a 10 per cent CBD (THC free), proprietary oral formulation in Canada.

Organigram looks to raise capital as cannabis stocks surge

Organigram (TSX:OGI), one of Canada's first cannabis stocks, announces an overnight marketed public offering of units for up to C$25 million.

Theratechnologies phases down preclinical oncology research

Biopharmaceutical company Theratechnologies (TSX:TH) announced it will phase down its preclinical oncology research activities.